Trust Point’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
Other funds holding NBIX
Trust Point's NBIX Position: Q3 2026 in Review
Trust Point sold out of Neurocrine Biosciences (NBIX) in Q3 2026, closing a stake of 1,455 shares — an estimated $245K sold.
Trust Point first reported a position in NBIX in Q2 2024 and held it in 6 quarters. The position peaked at $339K in Q4 2024. 630 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.
- Trust Point reported no remaining Neurocrine Biosciences position as of Q3 2026 after selling out during the quarter.
- Trust Point sold 1,455 Neurocrine Biosciences shares in Q3 2026, an estimated $245K.
- Trust Point first reported a position in Neurocrine Biosciences in Q2 2024 and held it in 6 quarters.
- Trust Point's Neurocrine Biosciences position peaked at $339K in Q4 2024.
- 630 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.
Based on Trust Point's 13F filing for Q3 2026, filed 27 Oct 2026.